To study effect of Ivermectin drug in patients infected with SARS-CoV-2 virus.
Not Applicable
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/06/025960
- Lead Sponsor
- Dr Rajkumar Nikalje
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Symptomatic patients infected with SARS-CoV-2 virus diagnosed on Real time PCR test, admitted to hospital.
Exclusion Criteria
1. Age less than 18 and more 70 years
2. Pregnant and lactating women
3. Patients not willing to give written informed consent
4. Seriously ill patients requiring intensive care
5. Known hypersensitivity to Ivermectin drug 6. Subjects who have participated in another investigational drug or research study within 30 days of screening.
7. Subjects who are using any medication or has any disease which in the judgment of the Investigator will interfere with the conduct or interpretation of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of Ivermectin on eradication of virus by testing for SARS-Co-V-2 by Real time PCR testTimepoint: day 7
- Secondary Outcome Measures
Name Time Method Duration of hospitalisationTimepoint: actual number of days of hospitalisation;Reduction in inflammatory markersTimepoint: Day 1, 5, 10;Resolution of signs and symptoms of COVID-19Timepoint: day 3, 5, 10;To assess Safety of ivermectinTimepoint: daily till day 15